Simplified Chinese
scroll down
16
2025-06
1. Project Name: Key Technologies for the Development of a Superbug Vaccine and Their Promotion and Application 2. Nominating Entity: Chongqing Municipality 3. Category and Level of Nomination Award: National Invention Award—First Prize or Second Prize 4. List of Major Intellectual Property Rights, Standards, and Specifications: | Intellectual Property (Standard) Category | Specific Name of Intellectual Property (Standard) | Country (Region) | Authorization Number (Standard Number) | Date of Authorization (Standard Publication) | Certificate Number (Standard Approval and Publication Authority) | Right Holder (Standard Drafting Organization) | Inventor (Standard Drafter) | Patent (Standard) | Validity Status | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | Invention Patent (Standard) | A Staphylococcus aureus Vaccine and Its Preparation Method | China | ZL2 |
16
2025-06
Public Notice Regarding Nomination Projects for the 2025 National Science and Technology Awards
Public Notice Regarding Nominations for the 2025 National Science and Technology Awards In accordance with Document No. 4 [2025] issued by the National Science and Technology Awards Office, “Notice on the Nomination Process for the 2025 National Science and Technology Awards,” and in order to ensure the smooth submission of applications for the 2025 National Science and Technology Awards, uphold the fairness of the awards, and strengthen public oversight of scientific and technological award activities, we hereby announce the project “Key Technologies for the Development of a Superbug Vaccine and Its Promotional Application,” in which our company has participated. The public notice period is from June 16 to June 20, 2025. During this period, should you have any objections to the nominated project, please submit your concerns to…
30
2025-04
On April 29, the Beijing Municipal Conference on Commending Model Workers, Advanced Workers, and Exemplary Collectives was solemnly held at the Beijing Convention Center. With approval from the CPC Beijing Municipal Committee and the Beijing Municipal People’s Government, Nie Xiaoqi, Deputy General Manager of Minhai Biotechnology, was awarded the honorary title of “Beijing Model Worker for 2025.” This year’s commendation placed particular emphasis on recognizing knowledge-based, skill‑driven, and innovation‑oriented workers, focusing on the capital’s major strategic priorities and key industries. Thanks to his outstanding contributions in vaccine production and quality management, Mr. Nie emerged as one of the distinguished representatives honored in the pharmaceutical and healthcare sector. For many years, Mr. Nie has been deeply committed to vaccine industrialization and quality assurance, successively holding positions in production management…
06
2025-01
Detailed Personal Achievements: Nie Xiaoqi is the Deputy General Manager of Beijing Minhai Biotechnology Co., Ltd. and currently serves as the company’s Head of Quality Management. He has previously held positions including Director of the Diphtheria–Tetanus–Pertussis Workshop in Vaccine Department II, Director of Vaccine Department IV, and Head of Production Management. During his tenure in the production system, he successfully facilitated the smooth market launch of eight products, including the Hib–DTP–IPV quadrivalent vaccine, the 23-valent pneumococcal vaccine, the 13-valent pneumococcal vaccine, and the human diploid cell‑derived rabies vaccine. As Head of Quality Management, he has organized a series of training programs on international regulatory requirements for GMP‑related personnel, invited WHO inspectors to provide advisory visits to the company, and recommended quality‑management professionals to attend major international conferences on quality management.
14
2024-10
In accordance with the “Decision of the State Council on Amending the Regulations on Environmental Protection Management of Construction Projects” (State Council Order No. 682) and the “Notice on the Issuance of the Interim Measures for Environmental Protection Acceptance upon Completion of Construction Projects” (Guohuan Gui Huanping [2017] No. 4), the “Environmental Protection Acceptance Report upon Completion (Phase I) for the Minhai Biotechnology International Vaccine Industrial Base Project” is hereby made public as follows: Project Name: Construction of the Minhai Biotechnology International Vaccine Industrial Base (Phase I) Project Undertaker: Beijing Minhai Biotechnology Co., Ltd. Publicized Contents: The environmental protection acceptance report upon completion, along with any other matters requiring clarification.
Contact Information
Customer Service Hotline
4001899806
Phone number
010-59613600
Official Website
Company Address
No. 35 Simiao Road and No. 25 Tianfu Street, Daxing Biomedical Industry Base, Zhongguancun Science Park, Daxing District, Beijing
WeChat Official Account
0
%